OTTAWA, ON, Nov. 15, 2024 /PRNewswire/ - Genomadix (genomadix.com), a global leader in point of need precision medicine diagnostics, announced today that it has entered into a know-how license agreement with Mayo Clinic to collaborate on the delivery of enhanced telestroke services in the U.S. Under the terms of the agreement, Mayo Clinic will grant Genomadix access to its specialized knowledge and technical expertise in the telestroke space, collaborating with Genomadix to expand the use of its

The One-Day Miracle Mission Providing the Gift of Sound™ Will Be Held November 18 BROOKLYN, N.Y., Nov. 15, 2024 /PRNewswire/ -- Miracle-Ear Foundation announces their Miracle Mission, which will provide the Gift of Sound™ to 100 Holocaust survivors with free hearing aids and related lifetime services on Monday, November 18 in Brooklyn. This Miracle Mission is in collaboration with the Auschwitz Jewish Center Foundation (AJCF), the Jewish Community Council of Greater Coney Island (JCCGCI) the Cl

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will present two posters related to its tRNA synthetase candidate ATYR0101 at the Keystone Symposia on Fibrosis: Inflammation, Drivers, and Therapeutic Resolution, which is scheduled to take place December

SEOUL, South Korea, Nov. 15, 2024 /PRNewswire/ -- Sky Labs announced that its groundbreaking wearable device, Apollon, has been named an "Honoree" in the Artificial Intelligence category at the CES 2025 Innovation Awards. Hosted by the Consumer Technology Association (CTA)®, the CES Innovation Awards program annually recognizes outstanding achievements in design and engineering across 33 categories of consumer technology. This prestigious honor marks Sky Labs' second award at CES, underscoring t

WALTHAM, Mass.--( BUSINESS WIRE )--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has authorized the repurchase of $4 billion of shares of its common stock in the open market or in negotiated transactions. The authorization has no expiration date. This replaces the company’s existing repurchase authorization, of which $1 billion was remaining. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world lea

MENLO PARK, Calif.--( BUSINESS WIRE )-- Synthekine Inc ., an engineered cytokine therapeutics company, today announced promising preclinical results with the murine version of its STK-009 + SYNCAR-001 program will be presented at the American College of Rheumatology (ACR) Convergence 2024 in Washington, D.C. This regimen demonstrated potential to treat autoimmune diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), without requiring lymphodepletion. Preclinical fin

JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization of GOHIBIC (vilobelimab), under exceptional circumstances for the treatment of adult patients with SARS-CoV-2-induced acute respira

The European Medicines Agency’s human medicines committee handed down a slew of positive recommendations for drugs on Friday, including Merck’s blockbuster cancer drug Keytruda and InflaRx’s monoclonal antibody Gohibic for Covid-19. The committee recommended label expansions for 11 drugs, including the Keytruda-pemetrexed-platinum chemotherapy combination for the first-line treatment of adult patients with unresectable non-epithelioid malignant pleural mesothelioma, and Bristol Meyers Squibb’s

MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression after one or more immune checkpoint inhibitor (ICI) therapy Two PRs were observed among 3 microsatellite instability high (MSI-H) ICI resistant patients (ORR 66.7%) with both responders having pancreatic cancer including one patient with 100% tumor regression and no progression of target and non-targe

MALVERN, Pa., Nov. 15, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that it has entered into a definitive agreement with MC2 Therapeutics ("MC2") to commercialize Wynzora® Cream (calcipotriene and betamethasone dipropionate) in Canada through Endo's subsidiary Paladin Pharma Inc. "We look forward to working with MC2 to make Wynzora® Cream available to Canadians who suffer from plaque psoriasis," said Livio Di Francesco, Vice President and General Manager of Paladin. "If approved